

RESEARCH

Open Access



Exosomal microRNAs in the DLK1-DIO3 imprinted region derived from cancer-associated fibroblasts promote progression of hepatocellular carcinoma by targeting hedgehog interacting protein

An-Li Jin^{1†}, Lin Ding^{1†}, Wen-Jing Yang¹, Te Liu^{1,7}, Wei Chen¹, Tong Li¹, Chun-Yan Zhang^{1,4}, Bai-Shen Pan^{1,5}, Shuang-Jian Qiu^{2,3}, Jian Zhou^{2,3}, Jia Fan^{2,3}, Wei Guo^{1,4,5,6,8}, Xin-Rong Yang^{2,3*} and Bei-Li Wang^{1,4,5*}

Abstract

Background: Hepatocellular carcinoma (HCC) is the sixth most commonly diagnosed cancer and third leading cause of cancer-related death worldwide in 2020. Exosomes derived from cancer-associated fibroblasts (CAFs-exo) can promote tumor progression in various human cancers. However, the underlying regulatory mechanism controlling how CAFs-exo can promote HCC progression remains poorly understood.

Methods: CAFs and para-cancer fibroblasts (PAFs) were isolated from HCC tissues and corresponding para-cancer tissues, then were cultured in vitro. CAFs and PAFs were characterized by immunofluorescence and western blot (WB) assays. Exosomes were isolated by ultracentrifugation, and characterized by transmission electron microscopy, nanoflow cytometry, and WB assay. The internalization of exosomes by HCC cells was observed under a fluorescence microscope. Cell Counting Kit-8 (CCK-8) assay was used to evaluate cell proliferation. Wound healing and transwell assays were used for migration and invasion experiments. RT-PCR assay was used to examine differentially expressed microRNAs (miRNAs) in exosomes and HCC cells. The TargetScan database was used to predict miRNA target genes. Hedgehog interacting protein (HHIP) expression analysis, prognostic analysis, and enrichment analysis of HHIP-related co-expressed genes were performed using the TIMER, UALCAN, Kaplan–Meier plotter, and LinkedOmics databases.

Results: CAFs-exo were internalized by HCC cells. CAFs-exo contributed to the aggressive phenotype of HCC cells, while inhibiting exosome secretion reversed these effects. Mechanistically, miRNAs in the DLK1-DIO3 imprinted region (miR-329-3p, miR-380-3p, miR-410-5p, miR-431-5p) were increased in HCC cells co-cultured with CAFs-exo

[†]An-Li Jin and Lin Ding have contributed equally to this work

*Correspondence: yang.xinrong@zs-hospital.sh.cn; wang.beili1@zs-hospital.sh.cn

¹ Department of Laboratory Medicine, Zhongshan Hospital, Fudan University, Shanghai 200032, People's Republic of China

² Department of Liver Surgery and Transplantation, Liver Cancer Institute, Zhongshan Hospital, Fudan University, Shanghai 200032, People's Republic of China

Full list of author information is available at the end of the article



compared with PAFs-exo. Expression of HHIP, a possible miR-431-5p target gene, was significantly downregulated in HCC cells. Low HHIP expression level in tumor tissues could predict poor prognosis in HCC patients. HHIP-related co-expressed genes were mainly associated with cell adhesion molecules.

Conclusions: CAFs-exo can promote HCC progression by delivering miRNAs in the DLK1-DIO3 imprinted region to HCC cells, subsequently inhibiting HHIP expression. HHIP is a potential prognostic biomarker in HCC.

Keyword: Hepatocellular carcinoma, Cancer-associated fibroblasts, Exosomes, DLK1-DIO3 microRNA cluster, Hedgehog interacting protein

Background

Hepatocellular carcinoma (HCC) accounts for 75% to 85% of primary liver cancer cases, which ranks as the sixth most commonly diagnosed cancer type and the third leading cause of cancer-related death worldwide in 2020 [1]. Although surgical resection remains the most effective HCC treatment method, only 20% to 30% of HCC patients have the opportunity for surgery because many are already at an advanced stage when they are diagnosed [2]. The underlying mechanisms of HCC progression are not fully understood. Therefore, it is critical to explore these mechanisms to support the further development of novel therapeutic strategies for HCC treatment.

The tumor microenvironment (TME) is considered a major contributor to tumor progression [3]. The TME is composed of tumor cells, innate and adaptive immune cells, cancer-associated fibroblasts (CAFs), and other cell types [4]. Several studies found that CAFs promoted tumor progression through their interaction with tumor cells [5, 6]. Because of the important role of CAFs in the TME, they are potential therapeutic targets for anti-cancer therapies [7]. Exosomes are cell-derived nanovesicles containing cargo that can include nucleic acids, proteins, and lipids. Exosomes function as major mediators of intercellular communication by transferring various genetic information within the cargo when secreted by one cell and taken up by another [8]. Exosomes derived from CAFs (CAFs-exo) could reportedly promote tumor progression in various human cancers [9, 10], suggesting that CAFs-exo played a significant role in the TME. However, the mechanisms by which CAFs-exo can promote HCC progression and details of the communication between CAFs-exo and HCC cells are still unclear.

MicroRNAs (miRNAs) are a class of small endogenous non-coding RNAs that are typically between 19 and 23 nucleotides (nt) in length. miRNAs inhibit gene expression post-transcriptionally by binding to the complementary 3' untranslated region (3'-UTR) of the mRNA of the target gene, leading to mRNA cleavage or translational inhibition [11]. Increasing evidences showed that miRNAs were frequently abnormally expressed in tumor tissues, suggesting that these

molecules had important roles in tumor progression and metastasis [12]. The DLK1-DIO3 imprinted region is located on human chromosome 14 and mouse chromosome 12, containing the paternally expressed genes delta-like homolog 1 (DLK1), retrotransposon-like gene 1 (RTL1), and type 3 deiodinase (DIO3), and the maternally expressed genes maternally expressed gene 3 (MEG3), MEG8, and antisense RTL1 [13]. In addition, the DLK1-DIO3 imprinted region contains 54 miRNAs, which represents one of the largest miRNA clusters in the human genome [14]. The miRNAs in the DLK1-DIO3 imprinted region are involved in the epithelial-mesenchymal transition (EMT) process and oncogenesis [15, 16]. However, the specific regulatory mechanisms of these miRNAs in the DLK1-DIO3 imprinted region in HCC cells remain unknown.

In this study, we explored the role and mechanisms of CAFs-exo in promoting HCC progression. Our data suggested that CAFs-exo could be internalized by HCC cells, delivering miRNAs in the DLK1-DIO3 imprinted region, and thus, promoting the aggressive phenotype of HCC cells. In vitro experiments showed that the expression of hedgehog interacting protein (HHIP) was inhibited in HCC cells co-cultured with CAFs-exo. Bioinformatics analysis further indicated that HHIP expression level was downregulated in HCC tissues, and low HHIP expression could predict poor prognosis in HCC patients. Our findings provide novel insights into HCC progression, which will contribute to the development of novel therapeutics for HCC treatment.

Methods and materials

Clinical specimens

Clinical samples were collected from HCC patients undergoing surgical resection in the Liver Cancer Institute, Zhongshan Hospital, Fudan University. HCC patients were diagnosed by hematoxylin–eosin staining without a history of radiotherapy or chemotherapy before surgical resection. Approval for the use of human specimens was obtained from the Research Ethics Committee of Zhongshan Hospital, Fudan University. Informed consent had been obtained from all patients.

Cell culture and transfection

HCC cell lines (PLC/PRF/5 and SMMC7721) were obtained from the Chinese Academy of Sciences (Shanghai, China). HCC cells were cultured in high-glucose Dulbecco's modified Eagle's medium (DMEM, Gibco BRL, Grand Island, NY) supplemented with 10% fetal bovine serum (FBS, Gibco BRL), 1% penicillin and 100 µg/ml streptomycin (Gibco BRL) at 37 °C with 5% CO₂. MiRNA mimics were designed and synthesized by GenePharma (Shanghai, China), and were transfected into HCC cells using a Lipo3000 kit (Invitrogen, Carlsbad, CA, USA) according to manufacturer's instructions.

Isolation and culture of CAFs and para-cancer fibroblasts (PAFs)

CAFs and PAFs were isolated from HCC tissues and corresponding para-cancer tissues respectively. Tissues were minced with a sterile blade into pieces (1 mm³) and were digested for 2 h at 37 °C in 10% FBS DMEM containing 1 mg/mL collagenase type IV (Sigma-Aldrich, Atlanta, GA, USA). Then samples were filtered through an 8 µm mesh to remove undigested debris and were cultured in DMEM/F12 (Gibco BRL) supplemented with 10% FBS, 1% penicillin and 100 µg/ml streptomycin at 37 °C with 5% CO₂. Non-adherent cells were removed by washing with PBS after 48 h. The adherent fibroblasts were incubated in a 24-well plate, and then transferred to a 25cm³ cell culture flask for cell expansion. Primary fibroblasts were used for experiments up to passage 10.

Immunofluorescence (IF) assay

Cells were fixed in 4% paraformaldehyde and blocked with 5% bovine serum albumin. Next, cells were incubated with anti-α-SMA (1:100, Cell Signaling Technology, CST, USA) and anti-Vimentin (1:100, CST) at 4 °C for a night, followed by incubation with 488-conjugated secondary antibody (CST) for 2 h. After washing with PBS, cells were counterstained with DAPI for observation under the microscope. Average optical density (AOD) was used for the quantification of the results of IF assay. AOD = integrated optical density (IOD) / Area.

Western blot (WB)

WB assay was carried out using standard procedures as previously described [17]. The antibodies used for WB assay were as follows: anti-α-SMA (CST), anti-Vimentin (CST), TSG101 (Abcam, Cambridge, MA), CD81 (CST), CD9 (CST), E-cadherin (CST), N-cadherin (CST), HHIP (Affinity Biosciences, Changzhou, China), and GAPDH (Beyotime, Shanghai, China). The protein level was standardized to GAPDH, and then standardized to experimental control. Densitometric analysis was performed using NIH Image J software.

Isolation of exosomes

The fibroblasts were incubated with 10% FBS DMEM/F12 for 48 h. The culture medium was collected, and then centrifuged at 1,000 × g for 5 min and 10,000 × g for 30 min to remove cell debris, followed by filtration through a 0.22 µm filter (Millipore, USA). Exosomes were pelleted by ultracentrifugation at 120,000 × g for 70 min for further in vitro experiments.

Characterization of exosomes

The morphology of exosomes was observed by the transmission electron microscopy analysis. The size distribution of exosomes was analyzed by the nanoflow cytometry analysis. The procedure of transmission electron microscopy analysis and nanoflow cytometry analysis was the same as our previous study [18].

Exosomes internalization assay

CAFs were labeled with fluorescent dye 1,1'-dioctadecyl-3,3,3',3'-tetramethylindocarbocyanine perchlorate (Dil, Thermo Scientific, USA), and incubated for 20 min at 37 °C. HCC cells were plated in a 24-well plate, followed by incubation with Dil-labeled CAFs for 24 h at 37 °C in the upper transwell chamber for observation under a fluorescence microscope.

Cell Counting Kit-8 (CCK-8), wound healing, and transwell assays

For CCK-8 assay, cells (2000 cells per well) were incubated in a 96-well plate. Cell viability were examined at 0 day, 1 day, 2 day, 3 day and 4 day. All operations were carried out according to manufacturer's instructions. The abilities of cell migration and invasion were detected by wound healing assay and transwell assay as previously described [17]. All experiments were conducted in triplicate.

RNA extraction and RT-PCR

Total RNA of cells was extracted by the RNA isolation kits (Qiagen, Germany). For mRNA detection, cDNA was synthesized by the Quantitect reverse transcription kit (Qiagen). All operations were carried out according to manufacturer's instructions. The mRNA expression levels of genes were quantified by SYBR Mix (Takara, Japan) and Roche real-time PCR detection system (Roche Diagnostics). The primers used in this study were as follows: KFL12: 5'-CCTCACCTTCTTCAACTTCAAC-3'(F), 5'-GCCTCCAACACCAGATGC-3'(R); KDM5A: 5'-AGGATAGGAATACCAGAGATG-3'(F), 5'-GAGCCACAGAAGCACAGG-3'(R); HHIP: 5'-GTGCTACGGCTGGATGTG-3'(F), 5'-TGGTGCTGTTGAGTGTGG-3'(R); GAPDH: 5'-CCACTCCTCCACCTT TGAC-3'(F), 5'-CACCACCCTGTTGCTGTAG-3'(R).

PCR conditions were as follows: 5 min at 95 °C, followed by 40 cycles of 95 °C for 10 s and 60 °C for 60 s. GAPDH was used as an internal control. For miRNAs detection, cDNA synthesis and quantitative RT-PCR detection were conducted by miRNA qRT-PCR detection kit (GeneCopoeia, Rockville, Maryland). The primers of miRNAs used in this study were designed and synthesized by GeneCopoeia. PCR conditions were as follows: 5 min at 95 °C, followed by 40 cycles of 95 °C for 10 s, 60 °C for 20 s, and 72 °C for 10 s. U6 was used as an internal control. The fold change was calculated according to the formula $2^{-\Delta\Delta Ct}$. Each reaction was performed in triplicate.

Bioinformatics analysis

The target genes of miRNAs were predicted by the TargetScan database (http://www.targetscan.org/vert_72/). The venn diagram was plotted by the VENN 2.1 (<https://bioinfo.gp.cnb.csic.es/tools/venny/>) [19]. The analysis of HHIP expression in human cancers was performed by the TIMER database (<https://cistrome.shinyapps.io/timer/>) [20]. The analysis of the differential expression of HHIP was performed in liver hepatocellular carcinoma (LIHC) cohort from The Cancer Genome Atlas (TCGA) database (<https://portal.gdc.cancer.gov/>), HCC cohorts from the Gene Expression Omnibus (GEO) database (<https://www.ncbi.nlm.nih.gov/>), and Liver Cancer-RIKEN, JP (LIRI-JP) cohort from the International Cancer Genome Consortium (ICGC) data portal (<https://dcc.icgc.org/>). The Kaplan–Meier (KM) survival curves were plotted using the KM plotter database (http://kmplot.com/analysis/index.php?p=service&cancer=liver_rnaseq) [21]. The analysis of the HHIP-related co-expressed genes in TCGA-LIHC cohort was performed using the LinkedOmics database (<http://www.linkedomics.org/>) [22]. Enrichment analysis was performed using the LinkInterpreter module of LinkedOmics. Gene set enrichment analysis (GSEA) tool was used to perform the enrichment analysis, including Gene Ontology (GO) terms biological processes (BP), cellular components (CC), and molecular functions (MF), and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathways [23–25].

Statistical analysis

SPSS software 16.0 and Graphpad prism 8.0 were used for statistical analysis. The χ^2 test, Fisher's exact test, Student's *t* test, and Mann–Whitney *U* test were used to evaluate the significance of differences in data between groups. $p < 0.05$ was considered statistically significant.

Results

Isolation and identification of CAFs and CAFs-derived exosomes

We first characterized a spindle-shaped morphology of PAFs and CAFs (Fig. 1A). IF and WB assays showed that both PAFs and CAFs expressed the mesenchymal marker (Vimentin), and the expression level of CAF-specific marker (α -SMA) was higher in CAFs compared with PAFs (Fig. 1B, C; Additional file 1: Fig. S1). We further isolated exosomes from the conditioned medium of CAFs (CAFs-CM) and PAFs (PAFs-CM) using ultracentrifugation. WB assay showed that the classic exosomal markers (TSG101, CD81, CD9) were expressed in both PAFs-derived exosomes (PAFs-exo) and CAFs-derived exosomes (CAFs-exo) (Fig. 1D; Additional file 1: Fig. S2). Transmission electron microscopy and nanoflow cytometry analysis also confirmed the typical cup-shaped morphology of exosomes, which ranged in size from 50 to 200 nm (Fig. 1E, F).


To determine whether CAFs-exo could be internalized by HCC cells, CAFs were labeled with fluorescent dye Dil, and were then incubated with HCC cells in the upper transwell chamber for 24 h. We found that red fluorescence signal was observed in HCC cells in the lower transwell chamber (Fig. 1G).

CAFs-exo can promote the aggressive phenotype of HCC cells

CCK-8 assay showed that CAFs-exo could promote cell proliferation compared with PAFs-exo (Fig. 2A). Wound healing and transwell assays demonstrated that CAFs-exo could enhance the migration and invasion rates in HCC cells compared with PAFs-exo (Fig. 2B, C). Moreover, co-cultures with CAFs-exo resulted in lower E-cadherin expression and higher N-cadherin expression in HCC cells (Fig. 2D; Additional file 1: Fig. S3). GW4869 treatment was used to inhibit exosome secretion from CAFs, which reversed the observed effects in HCC cells (Fig. 3A–D; Additional file 1: Fig. S3).

HHIP expression is inhibited by the CAFs-exo-derived miRNAs in the DLK1-DIO3 imprinted region

Luk et al. found that 21 miRNAs in the DLK1-DIO3 miRNA cluster were coordinately upregulated in a subset of HCC tissues, and HCC patients with overexpression of these miRNAs showed significantly poorer overall survival (OS) [26]. To investigate the potential molecules responsible for the role of CAFs-exo in promoting HCC progression, the expression levels of these miRNAs were detected by RT-PCR assay. The results demonstrated that 11 miRNAs were highly expressed in CAFs-exo compared with PAFs-exo (Fig. 4A). To



identify the specific miRNAs that were transferred to HCC cells from CAFs-exo, we analyzed the expression levels of these miRNAs in HCC cells. The results showed that miR-329-3p, miR-380-3p, miR-410-5p, and miR-431-5p were upregulated in PLC/PRF/5 and SMMC7721 cells treated with CAFs-exo (Fig. 4B).


Kruppel like factor 12 (KLF12), lysine demethylase 5A (KDM5A), and HHIP were predicted to be target genes of miR-329-3p, miR-380-3p, miR-410-5p, and miR-431-5p using the TargetScan database (Fig. 4C). Because it was the most downregulated gene in the RT-PCR results, HHIP was selected for further investigations (Fig. 4D). We detected the expression level of HHIP in HCC cells treated with 4 miRNA mimics. The results showed that HHIP expression was decreased in HCC cells treated with miR-431-5p mimic at both the mRNA and protein level, indicating that HHIP was a

potential target gene of miR-431-5p in HCC (Fig. 4E, F; Additional file 1: Fig. S4).

HHIP is significantly downregulated in HCC tissues

The TIMER database was used to explore the expression level of HHIP in human cancers, which showed that HHIP was downregulated in a variety of tumor tissues (Fig. 5A). The analysis of the differential expression of HHIP in HCC cohorts from the TCGA database, GEO database, and ICGC database also confirmed that HHIP expression was decreased in HCC tissues (Fig. 5B–G).

We further explored HHIP expression level in HCC subgroups compared with normal tissues based on several clinical characteristics (individual cancer stages, race, gender, age, weight, tumor grade, nodal metastasis status, TP53 mutation status, histological subtypes) using the UALCAN database. HHIP downregulation




was observed in different subgroups of HCC (Fig. 6A–I; Additional file 2: Table S1), implying that HHIP was a potential prognostic biomarker for HCC patients.

Prognostic value of HHIP expression in HCC

KM survival curves were used to assess the prognostic value of HHIP in the TCGA-LIHC cohort using the KM plotter database. The results showed that HCC patients with low HHIP expression level had shorter relapse-free survival (RFS), progression-free survival (PFS), and disease-specific survival (DSS) (Fig. 7A–C), indicating that low HHIP expression was associated with a poor outcome in HCC. In addition, we explored the prognostic significance of HHIP expression in the low recurrent risk subgroups of HCC. We found that HCC patients with low HHIP expression level had shorter OS in the HBV-None group, shorter RFS in the stage I-II group, alcohol consumption-None group, and vascular invasion-None group, shorter PFS in the grade I group, and shorter DSS in the HBV-None group (Fig. 7D–I).

GSEA analysis of HHIP-related co-expressed genes in HCC

To explore the underlying mechanisms of HHIP in HCC progression, the LinkedOmics database was used to identify the HHIP-related co-expressed genes in the TCGA-LIHC cohort. Overall, 11,748 genes were positively related to HHIP expression, while 8,174 genes were negatively related to HHIP expression (Fig. 8A). The top 50 HHIP-related co-expressed genes were shown in a heat map (Fig. 8B, C). GSEA analysis was used to analyze the GO terms and KEGG pathways of HHIP-related co-expressed genes. GO analysis showed that HHIP-related co-expressed genes were involved in cell-substrate adhesion and cell adhesion mediator activity (Fig. 8D–F; Additional file 2: Table S2), while KEGG analysis demonstrated that HHIP-related co-expressed genes were mainly associated with cell adhesion molecules (Fig. 8G; Additional file 2: Table S2).



Discussion

HCC is one of the most prevalent malignancies worldwide with high rates of recurrence and metastasis [27]. There is an urgent need to understand the mechanisms of HCC progression to help develop novel therapeutic strategies for HCC. Here, we found that CAFs-exo could be internalized by HCC cells, and promoted cell proliferation, migration, and invasion. Further investigations revealed that miRNAs in the DLK1-DIO3 imprinted region were transferred from CAFs-exo to HCC cells, inhibiting the expression of HHIP in these cells. We then analyzed data from TCGA database, and found that HHIP expression was decreased in HCC tissues, moreover, it was positively correlated with OS of HCC patients. Functional enrichment analysis suggested that the function of HHIP was likely dependent on the regulation of cell adhesion in HCC. These findings help elucidate the communication details between CAFs-exo and HCC cells, and indicate that HHIP is a promising prognostic biomarker in HCC patients.

Exosomes secreted by tumor cells can modulate various biological processes in tumor progression, including tumor angiogenesis, metastasis, and immune escape [28]. Our results demonstrated that CAFs-exo contributed to the aggressive phenotype of HCC cells in vitro. These findings were in accordance with a previous report that showed that CAFs-exo could enhance EMT and cell stemness, leading to metastasis and chemotherapy resistance in colorectal cancer [29]. Increasing evidences had shown that miRNAs derived from tumor cells could be encapsulated in exosomes, and delivered to recipient cells to exert cancer-supporting functions by binding to sequences in the 3'-UTR of target mRNAs [30]. The DLK1-DIO3 miRNA cluster plays a significant role in cancer self-renewal and maintenance of the aggressive phenotype [31]. MiR-380-3p was upregulated in bladder cancer tissues, and promoted cell proliferation and mitochondrial respiration [32]. MiR-410-5p could promote tumor growth through degradation of miR-410-3p, which prevented miR-410-3p-mediated suppression of tumor angiogenesis [33]. Overexpression of miR-431-5p






Fig. 4 MicroRNAs (miRNAs) in the DLK1-DIO3 imprinted region derived from CAFs-exo inhibit HHIP expression in HCC cells. **A** The expression levels of miRNAs in the DLK1-DIO3 imprinted region derived from PAFs-exo and CAFs-exo were detected by RT-PCR assay. **B** The expression levels of miRNAs in the DLK1-DIO3 imprinted region in HCC cells co-cultured with PAFs-exo and CAFs-exo were detected by RT-PCR assay. **C** The target genes of miR-329-3p, miR-380-3p, miR-410-5p, and miR-431-5p were predicted using the TargetScan database. **D** The mRNA expression levels of KLF12, KDM5A, and HHIP in HCC cells were detected by RT-PCR assay. **E, F** The mRNA and protein expression levels of HHIP in HCC cells transfected with 4 miRNA mimics were detected by RT-PCR and WB assays






could promote colony formation and inhibited apoptosis in cervical adenocarcinoma [34]. However, the role and specific mechanisms of the DLK1-DIO3 miRNA cluster in HCC progression remain unclear.

KLF12 is a member of kruppel-like factor family, and its tumor suppressive and oncogenic functions in human cancers are increasingly appreciated [35]. KDM5A belongs to the KDM5 Jumonji histone demethylase subfamily, and is responsible for driving cell growth, differentiation, multi-drug resistance, invasion, and metastasis [36]. HHIP binds to all Hh ligands, and acts as a negative regulator of the Hh/GLI signaling pathway, which is abnormally activated in colorectal cancer, prostate cancer, and other cancers [37]. In this study, we found that low HHIP expression level could predict worse prognosis in HCC patients. Moreover, the prognostic value of HHIP was noted in HCC

patients without HBV infection and alcohol consumption. The prognostic significance of HHIP in these low recurrent risk subgroups can help clinicians identify patients at high risk of recurrence and implement appropriate postoperative adjuvant treatments. However, the clinical significance of HHIP expression in HCC requires further investigation.

Previous studies reported that HHIP overexpression could inhibit cell proliferation, migration, and invasion in HCC [38], gastric cancer [39], and lung cancer [40]. A previous study reported that DNA hypermethylation and/or loss of heterozygosity resulted in the downregulation of HHIP transcription, and Hh signal activation through the inactivation of HHIP was implicated in the pathogenesis of HCC [41]. Our data showed that HHIP-related co-expressed genes were closely associated with cell adhesion, indicating that HHIP might play an



important role in HCC progression through regulating cell adhesion molecules.

Our study has several limitations. The results showed that miRNAs in the DLK1-DIO3 imprinted region were transferred from CAFs-exo to HCC cells, and promoted HCC progression by targeting HHIP. However,

the role and mechanisms of HHIP in HCC progression need further clarification. Additionally, we found that HHIP expression level was decreased in HCC tissues, and low HHIP expression could predict poor prognosis in the TCGA-LIHC cohort. However, it should




Fig. 8 Enrichment analysis of HHIP-related co-expressed genes in the TCGA-LIHC cohort. **A** Analysis of HHIP-related co-expressed genes was performed using the LinkedOmics database. **B, C** The top 50 genes that were positively and negatively correlated with HHIP expression level were shown in heat maps. **D–G** Analysis of the significantly enriched Gene Ontology (GO) terms and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathways (<https://www.kegg.jp/kegg/>) of HHIP-related co-expressed genes was performed using the Gene set enrichment analysis (GSEA) tool in the LinkedOmics database

be noted that the potential prognostic value of HHIP requires additional validation in more HCC cohorts.

Conclusion

In this study, we demonstrate that CAFs-exo are internalized by HCC cells, and can promote the aggressive phenotype of HCC cells. The expression levels of miR-329-3p, miR-380-3p, miR-410-5p, and miR-431-5p are upregulated in HCC cells treated with CAFs-exo compared with PAFs-exo, while HHIP expression level is significantly decreased. HHIP is a potential target gene of miR-431-5p in HCC. Bioinformatics analysis suggests that the function of HHIP in HCC may depend on the regulation of cell adhesion molecules. HHIP is expected to be a promising prognostic biomarker for HCC patients.

Supplementary Information

The online version contains supplementary material available at <https://doi.org/10.1186/s12876-022-02594-2>.

Additional file 1: Supplementary figures.

Additional file 2: Supplementary tables.

Acknowledgements

The authors thank all the patients included in our study.

Author contributions

B-LW, X-RY, WG, JF, JZ, S-JQ, B-SP, and C-YZ were responsible for study conception and design; A-LJ, LD, WC, and TL were responsible for material preparation and data collection; A-LJ and LD were responsible for data analysis; A-LJ, LD, W-JY, TL, X-RY, and B-LW were responsible for drafting and revision of the manuscript. All authors read and approved the final manuscript.

Funding

This study was supported by grants from the National Natural Science Foundation of China grants (81902139, 82172348, 81872355, 81830102, 81802991, 81972000, 82072715, 82150004), the National Key Research & Development Program of China (2019YFC1315800, 2019YFC1315802, 2021YFC2501900), the State Key Program of National Natural Science of China grants (81830102), the Shanghai Municipal Health Commission Collaborative Innovation Cluster Project (2019CXJQ02), the Shanghai "Rising Stars of Medical Talent" Youth Development Program (Outstanding Youth Medical Talents), the Projects from the Shanghai Science and Technology Commission (21140900300, 22531901800), the Constructing Project of Clinical Key Disciplines in Shanghai (shslczdzk03302), the Projects from the Shanghai Municipal Health Commission (201940075), the Specialized Fund for the Clinical Researches of Zhongshan Hospital, Fudan University (2018ZSLC05, 2020ZSLC54, 2020ZSLC31), the Projects from Science Foundation of Zhongshan Hospital, Fudan University (2021ZSCX28), the Projects from Excellent backbone of Zhongshan Hospital, Fudan University (2021ZSGG08), the Key Medical and Health Projects of Xiamen (YDZX20193502000002), and the Shanghai Medical Key Specialty (ZK2019B28).

Availability of data and materials

The datasets analyzed for this study could be found in The Cancer Genome Atlas database (<https://portal.gdc.cancer.gov>), Gene Expression Omnibus database (<https://www.ncbi.nlm.nih.gov>), and International Cancer Genome Consortium data portal (<https://dcc.icgc.org/>). All data generated or analyzed during this study are included in this published article [and its supplementary information files].

Declarations

Ethics approval and consent to participate

The study was approved by the Research Ethics Committee of Zhongshan Hospital, Fudan University. The authors state that they have obtained appropriate institutional review board approval or have followed the principles outlined in the Declaration of Helsinki for all human or animal experimental investigations. Informed consent has been obtained from all the participants involved.

Consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

Author details

¹Department of Laboratory Medicine, Zhongshan Hospital, Fudan University, Shanghai 200032, People's Republic of China. ²Department of Liver Surgery and Transplantation, Liver Cancer Institute, Zhongshan Hospital, Fudan University, Shanghai 200032, People's Republic of China. ³Key Laboratory of Carcinogenesis and Cancer Invasion, Ministry of Education, Shanghai 200032, People's Republic of China. ⁴Department of Laboratory Medicine, Xiamen Branch, Zhongshan Hospital, Fudan University, Xiamen 361015, People's Republic of China. ⁵Department of Laboratory Medicine, Wusong Branch, Zhongshan Hospital, Fudan University, Shanghai 200940, People's Republic of China. ⁶Cancer Center, Zhongshan Hospital, Fudan University, Shanghai 200032, People's Republic of China. ⁷Shanghai Geriatric Institute of Chinese Medicine, Shanghai University of Traditional Chinese Medicine, Shanghai 200031, People's Republic of China. ⁸Branch of National Clinical Research Center for Laboratory Medicine, Shanghai 200031, People's Republic of China.

Received: 24 June 2022 Accepted: 24 November 2022

Published online: 08 December 2022

References

- Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. *CA Cancer J Clin.* 2021;71(3):209–49.
- Zhou J, Sun H, Wang Z, et al. Guidelines for the diagnosis and treatment of hepatocellular carcinoma (2019 Edition). *Liver Cancer.* 2020;9(6):682–720.
- He Z, Zhang S. Tumor-associated macrophages and their functional transformation in the hypoxic tumor microenvironment. *Front Immunol.* 2021;12:741305.
- Oura K, Morishita A, Tani J, Masaki T. Tumor immune microenvironment and immunosuppressive therapy in hepatocellular carcinoma: a review. *Int J Mol Sci.* 2021;22(11):5801.
- Li Y, Wang R, Xiong S, et al. Cancer-associated fibroblasts promote the stemness of CD24(+) liver cells via paracrine signaling. *J Mol Med (Berl).* 2019;97(2):243–55.
- Shimizu M, Koma YI, Sakamoto H, et al. Metallothionein 2A expression in cancer-associated fibroblasts and cancer cells promotes esophageal squamous cell carcinoma progression. *Cancers (Basel).* 2021;13(18):4552.
- Asif PJ, Longobardi C, Hahne M, Medema JP. The role of cancer-associated fibroblasts in cancer invasion and metastasis. *Cancers (Basel).* 2021;13(18):4720.
- Liu J, Ren L, Li S, et al. The biology, function, and applications of exosomes in cancer. *Acta Pharm Sin B.* 2021;11(9):2783–97.
- Fan JT, Zhou ZY, Luo YL, et al. Exosomal lncRNA NEAT1 from cancer-associated fibroblasts facilitates endometrial cancer progression via miR-26a/b-5p-mediated STAT3/YKL-40 signaling pathway. *Neoplasia.* 2021;23(7):692–703.
- Shi H, Huang S, Qin M, et al. Exosomal circ_0088300 derived from cancer-associated fibroblasts acts as a miR-1305 sponge and promotes gastric carcinoma cell tumorigenesis. *Front Cell Dev Biol.* 2021;9:676319.
- Bartel DP. MicroRNAs: target recognition and regulatory functions. *Cell.* 2009;136(2):215–33.
- Fu Z, Wang L, Li S, et al. MicroRNA as an important target for anticancer drug development. *Front Pharmacol.* 2021;12:736323.
- Irving MD, Buiting K, Kanber D, et al. Segmental paternal uniparental disomy (patUPD) of 14q32 with abnormal methylation elicits the characteristic features of complete patUPD14. *Am J Med Genet A.* 2010;152A(8):1942–50.
- Benetos L, Hatzimichael E, Londin E, et al. The microRNAs within the DLK1-DIO3 genomic region: involvement in disease pathogenesis. *Cell Mol Life Sci.* 2013;70(5):795–814.
- Valdmanis PN, Kim HK, Chu K, et al. miR-122 removal in the liver activates imprinted microRNAs and enables more effective microRNA-mediated gene repression. *NAT Commun.* 2018;9(1):5321.
- Wang W, Ying Y, Xie H, et al. miR-665 inhibits epithelial-to-mesenchymal transition in bladder cancer via the SMAD3/SNAI1 axis. *Cell Cycle.* 2021;20(13):1242–52.
- Ma XL, Shen MN, Hu B, et al. CD73 promotes hepatocellular carcinoma progression and metastasis via activating PI3K/AKT signaling by inducing Rap1-mediated membrane localization of P110beta and predicts poor prognosis. *J Hematol Oncol.* 2019;12(1):37.
- Lyu L, Yang W, Yao J, et al. The diagnostic value of plasma exosomal hsa_circ_0070396 for hepatocellular carcinoma. *Biomark Med.* 2021;15(5):359–71.
- Agarwal V, Bell GW, Nam JW, Bartel DP. Predicting effective microRNA target sites in mammalian mRNAs. *Elife.* 2015;4:e05005.
- Li T, Fan J, Wang B, et al. TIMER: a web server for comprehensive analysis of tumor-infiltrating immune cells. *Cancer Res.* 2017;77(21):e108–10.
- Menyhart O, Nagy A, Gyorffy B. Determining consistent prognostic biomarkers of overall survival and vascular invasion in hepatocellular carcinoma. *R Soc Open Sci.* 2018;5(12):181006.
- Vasaikar SV, Straub P, Wang J, Zhang B. LinkedOmics: analyzing multi-omics data within and across 32 cancer types. *Nucleic Acids Res.* 2018;46(D1):D956–63.
- Kanehisa M, Goto S. KEGG: kyoto encyclopedia of genes and genomes. *Nucleic Acids Res.* 2000;28(1):27–30.
- Kanehisa M. Toward understanding the origin and evolution of cellular organisms. *Protein Sci.* 2019;28(11):1947–51.
- Kanehisa M, Furumichi M, Sato Y, Kawashima M, Ishiguro-Watanabe M. KEGG for taxonomy-based analysis of pathways and genomes. *Nucleic Acids Res (2022).*
- Luk JM, Burchard J, Zhang C, et al. DLK1-DIO3 genomic imprinted microRNA cluster at 14q32.2 defines a stemlike subtype of hepatocellular carcinoma associated with poor survival. *J Biol Chem.* 2011;286(35):30706–13.

27. Kanwal F, Singal AG. Surveillance for hepatocellular carcinoma: current best practice and future direction. *Gastroenterology*. 2019;157(1):54–64.
28. Wang M, Zhang B. The immunomodulation potential of exosomes in tumor microenvironment. *J Immunol Res*. 2021;3710372 (2021).
29. Hu JL, Wang W, Lan XL, et al. CAFs secreted exosomes promote metastasis and chemotherapy resistance by enhancing cell stemness and epithelial-mesenchymal transition in colorectal cancer. *Mol Cancer*. 2019;18(1):91.
30. Zhu L, Zhao L, Wang Q, et al. Circulating exosomal miRNAs and cancer early diagnosis. *Clin Transl Oncol*. 2021;24(3):393–406.
31. Chang C, Liu T, Huang Y, et al. MicroRNA-134–3p is a novel potential inhibitor of human ovarian cancer stem cells by targeting RAB27A. *Gene*. 2017;605:99–107.
32. Wu S, Deng H, He H, et al. The circ_0004463/miR-380-3p/FOXO1 axis modulates mitochondrial respiration and bladder cancer cell apoptosis. *Cell Cycle*. 2020;19(24):3563–80.
33. Wang J, Ye H, Zhang D, et al. Cancer-derived circulating MicroRNAs promote tumor angiogenesis by entering dendritic cells to degrade highly complementary MicroRNAs. *Theranostics*. 2017;7(6):1407–21.
34. Xu J, Lu W. CircSPIDR acts as a tumour suppressor in cervical adenocarcinoma by sponging miR-431-5p and regulating SORCS1 and CUBN expression. *Aging (Albany NY)*. 2021;13(14):18340–59.
35. Tetreault MP, Yang Y, Katz JP. Kruppel-like factors in cancer. *Nat Rev Cancer*. 2013;13(10):701–13.
36. Yang GJ, Zhu MH, Lu XJ, et al. The emerging role of KDM5A in human cancer. *J Hematol Oncol*. 2021;14(1):30.
37. Sigafos AN, Paradise BD, Fernandez-Zapico ME. Hedgehog/GLI signaling pathway: transduction, regulation, and implications for disease. *Cancers (Basel)*. 2021;13(14):3410.
38. Bo C, Li X, He L, et al. A novel long noncoding RNA HHIP-AS1 suppresses hepatocellular carcinoma progression through stabilizing HHIP mRNA. *Biochem Biophys Res Commun*. 2019;520(2):333–40.
39. Song Y, Tu J, Cheng Y, et al. HHIP overexpression suppresses human gastric cancer progression and metastasis by reducing its CpG Island Methylation. *Front Oncol*. 2020;10:1667.
40. Zhao JG, Wang JF, Feng JF, Jin XY, Ye WL. HHIP overexpression inhibits the proliferation, migration and invasion of non-small cell lung cancer. *PLoS ONE*. 2019;14(11):e225755.
41. Tada M, Kanai F, Tanaka Y, et al. Down-regulation of hedgehog-interacting protein through genetic and epigenetic alterations in human hepatocellular carcinoma. *Clin Cancer Res*. 2008;14(12):3768–76.

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Ready to submit your research? Choose BMC and benefit from:

- fast, convenient online submission
- thorough peer review by experienced researchers in your field
- rapid publication on acceptance
- support for research data, including large and complex data types
- gold Open Access which fosters wider collaboration and increased citations
- maximum visibility for your research: over 100M website views per year

At BMC, research is always in progress.

Learn more biomedcentral.com/submissions

